News

 

Amplexa initiates cooperation with Biotexcel consulting further expanding our interface with experts in the field.

More
 

Amplexa pursues its investments in cutting edge technology with achievement of NGS platforms. With the capability to perform massive parallel sequencing using PGM (Personal Genome Machine) the construction of panels for cancer, epilepsy or population specific gene variant panels are now at hand. Acquisition of Ion Torrent technology further allows whole genome CNV detection, RNA seq, ChipSeq and numerous other applications.

More
 

Amplexa initiates cooperation with SwissChekUp providing analysis of breast and colon cancer to the healthcare sector in Switzerland.

More
 

As part of our solutions in diagnosing individuals with various epilepsies Amplexa has established analysis of the PCDH19 gene. Mutations in PCDH19 has been reported in SCN1A negative patients with Dravet like symptoms and in patients with severe self destructive aggressive behaviour.

More